From Name:
From Email:
To Name:
To Email:

Optional Message:

FDA approves first new drug for AML since 1990

from Medscape

The U.S. Food and Drug Administration approved the kinase inhibitor midostaurin (Rydapt, Novartis), in combination with chemotherapy, for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) who have the FLT3 genetic mutation. Midostaurin is the first new drug approved for the treatment of AML since 1990. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063